ZFP36 disruption is insufficient to enhance the function of mesothelin-targeting human CAR-T cells
Abstract Loss of inflammatory effector function, such as cytokine production and proliferation, is a fundamental driver of failure in T cell therapies against solid tumors. Here, we used CRISPR/Cas9 to genetically disrupt ZFP36, an RNA binding protein that regulates the stability of mRNAs involved i...
Main Authors: | David Mai, Tifara Boyce, Aakash Mehta, Jordan Reff, John Scholler, Neil C. Sheppard, Carl H. June |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-02-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-024-53769-8 |
Similar Items
-
261 Synergistic antitumor effects of mouse mesothelin-directed CAR (mmeso-CAR) T cells and αCD40 in a syngeneic model of PDAC
by: Carl H June, et al.
Published: (2023-11-01) -
The RNA-binding proteins Zfp36l1 and Zfp36l2 act redundantly in myogenesis
by: Hema Bye-A-Jee, et al.
Published: (2018-12-01) -
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
by: Xuejia Zhai, et al.
Published: (2023-02-01) -
ZFP36L2 Role in Thyroid Functionality
by: Francesco Albano, et al.
Published: (2021-08-01) -
The RNA binding proteins ZFP36L1 and ZFP36L2 are dysregulated in airway epithelium in human and a murine model of asthma
by: Jennifer Rynne, et al.
Published: (2023-10-01)